FDA approves Roche’s Xofluza for patients at high risk of developing flu-related complications

FDA approves Roche’s Xofluza for patients at high risk of developing flu-related complications

Submitted by admin on October 18, 2019 - 7:48pm
Source: 
Pharmaceutical Business Review
News Tags: 
Roche
FDA
Xofluza
vaccines
influenza
Headline: 
FDA approves Roche’s Xofluza for patients at high risk of developing flu-related complications
snippet: 

The FDA has approved the company’s supplemental new drug application (sNDA) for Xofluza to treat acute, uncomplicated influenza, or flu, in people 12 years of age and older

Do Not Allow Advertisers to Use My Personal information